Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer

MLA

H. Letocha, et al. “Impact of Tumour RAS/BRAF Status in a First-Line Study of Panitumumab + FOLFIRI in Patients with Metastatic Colorectal Cancer.” British Journal of Cancer, vol. 115, no. 10, Oct. 2016, pp. 1215–22. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....11a2a5efefc5bce22f3066c9eaeb8152&authtype=sso&custid=ns315887.

APA

H. Letocha, Richard Greil, Michael Boedigheimer, Kelly S. Oliner, Eva Fernebro, Gaston Demonty, Meinolf Karthaus, Laurent Mineur, Ying Zhang, Brian Twomey, Ralf-Dieter Hofheinz, Josef Thaler, & Claus-Henning Köhne. (2016). Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer. British Journal of Cancer, 115(10), 1215–1222.

Chicago

H. Letocha, Richard Greil, Michael Boedigheimer, Kelly S. Oliner, Eva Fernebro, Gaston Demonty, Meinolf Karthaus, et al. 2016. “Impact of Tumour RAS/BRAF Status in a First-Line Study of Panitumumab + FOLFIRI in Patients with Metastatic Colorectal Cancer.” British Journal of Cancer 115 (10): 1215–22. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....11a2a5efefc5bce22f3066c9eaeb8152&authtype=sso&custid=ns315887.